NEW YORK, Nov. 6 – Gilead Sciences has sold an exclusive license to its aptamer-based IP for $17.5 million to Archemix, a privately held biotechnology company based in Cambridge, Mass., the company announced on Tuesday.
The deal, which Archemix said will complement its existing aptamer IP, gives the company “a broad spectrum” of DNA-based tools that it plans to use in drug discovery and development, it said.
“Based on this technology, we are developing platforms that can be used both in vitro and in vivo to take a snapshot of the level and state of all major networks of proteins inside a cell,” Martin Stanton, president of Archemix, said in a statement.
Financial terms of the deal, which also allows Archemix to sub-license the aptamer IP, were not disclosed.
Archemix said it has already developed aptamer-based tools to perform both in vitro and in vivo multiplex assays that it claims can monitor several pathways or proteins in a single assay. The company, which was founded in May, said it will use this technology to develop “novel screens” to help researchers evaluate the specificity and potential toxicity of new compounds early on in the drug-discovery process.